Je was op zoek naar: administrationsrelaterede (Deens - Engels)

administrationsrelaterede reaktioner
administration-related reactions

administrationsrelaterede reaktioner/overfølsomhed
administration-related reactions/hypersensitivity

i sparkthera rapporteredes ingen svære administrationsrelaterede reaktioner.
insparkthera, no severe administration-related reactions were reported.

i sparkthera studiet rapporteredes ingen svære administrationsrelaterede reaktioner.
in trial sparkthera, no severe administration-related reactions were reported.

præmedicinering kan anvendes for at reducere risikoen for, at administrationsrelaterede reaktioner opstår.
pre-medication may be used to reduce risk of occurrence of arrs.

1 angiver bivirkninger, som er rapporteret i stor udstrækning i forbindelse med administrationsrelaterede reaktioner.
1 denotes adverse reactions that are reported largely in association with administration-related reactions.

alle svære administrationsrelaterede reaktioner ved herceptin subkutan formulering opstod ved samtidig administration af kemoterapi.
all of the severe arrs with the herceptin subcutaneous formulation occurred during concurrent administration with chemotherapy.

patienter skal observeres for administrationsrelaterede reaktioner i 6 timer efter første injektion og i to timer efter efterfølgende injektioner.
patients should be observed for arrs for six hours after the first injection and for two hours after subsequent injections.

der er i kliniske studier set administrationsrelaterede reaktioner hos op til 50 % af patienter behandlet med mabthera subkutan formulering.
administration related reactions have been observed in up to 50% of patients treated with mabthera subcutaneous formulation in clinical trials.

administrationsrelaterede reaktioner: 37,2 % versus 47,8 % i henholdsvis intravenøs formulering og subkutan formulering.
administration-related reactions: 37.2 % versus 47.8 % for the intravenous formulation versus subcutaneous formulation, respectively during the treatment phase;

hyppigheden af administrationsrelaterede reaktioner af alle grader varierede mellem studierne afhængigt af indikation og metode til dataindsamling og afhængigt af, om trastuzumab blev givet samtidig med kemoterapi eller som monoterapi.
the rate of arrs of all grades varied between studies depending on the indication, the data collection methodology, and whether trastuzumab was given concurrently with chemotherapy or as monotherapy.

i det pivotale studie var hyppigheden af administrationsrelaterede reaktioner 37,2 % ved intravenøst formuleret herceptin og 47,8 % ved herceptin subkutan formulering.
in the pivotal trial, the rate of all grade arrs was 37.2 % with the herceptin intravenous formulation and 47.8 % with the herceptin subcutaneous formulation; severe grade 3 reactions were reported in

i sabrina rapporteredes svære administrationsrelaterede reaktioner (grad ≥3) hos 2 patienter (2 %) efter subkutan administration af mabthera.
insabrina, severe administration-related reactions (grade≥3) were reported in two patients (2%) following administration of mabthera subcutaneous formulation.

i sabrina studiet rapporteredes svære administrationsrelaterede reaktioner (grad ≥3) hos 2 patienter (2 %) efter subkutan administration af mabthera.
in trial sabrina, severe administration-related reactions (grade≥3) were reported in two patients (2%) following administration of mabthera subcutaneous formulation .

i sawyer studiet (bo25341), rapporteredes svære administrationsrelaterede reaktioner (grad ≥3) hos 4 patienter (5 %) efter subkutan administration af mabthera.
in sawyer (bo25341), severe administration-related reactions (grade ≥3) were reported in four patients (5%) following mabthera subcutaneous administration.